Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Creating a monster: non-adherence underlying late transplant rejection.

Goebel J, Pai A.

Pediatr Transplant. 2012 Jun;16(4):312-4. doi: 10.1111/j.1399-3046.2012.01687.x. Epub 2012 Apr 11. No abstract available.

PMID:
22489913
2.

Re: letter to the editor on "Alemtuzumab induction in renal transplantation: a meta-analysis and systemic review".

Zhang X, Wang L.

Transpl Immunol. 2013 Mar;28(2-3):72. doi: 10.1016/j.trim.2013.01.002. Epub 2013 Jan 23. No abstract available.

PMID:
23352934
3.

Extended daclizumab monotherapy for rejection-free survival in non-adherent adolescent recipients of renal allografts.

Chaudhuri A, Salvatierra O Jr, Sarwal MM.

Pediatr Transplant. 2009 Nov;13(7):927-32. doi: 10.1111/j.1399-3046.2008.01081.x. Epub 2008 Oct 31.

PMID:
19017291
4.

HLA-DR matching in organ allocation: balance between waiting time and rejection in pediatric kidney transplantation.

Vu LT, Baxter-Lowe LA, Garcia J, McEnhill M, Summers P, Hirose R, Lee M, Stock PG.

Arch Surg. 2011 Jul;146(7):824-9. doi: 10.1001/archsurg.2011.147.

PMID:
21768429
5.

Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.

Gabardi S, Catella J, Martin ST, Perrone R, Chandraker A, Magee CC, McDevitt-Potter LM.

Ann Pharmacother. 2011 Sep;45(9):e48. doi: 10.1345/aph.1Q019. Epub 2011 Aug 2.

PMID:
21811001
6.

The cam-path forward.

Kirk AD.

Am J Transplant. 2013 Jan;13(1):9-10. doi: 10.1111/j.1600-6143.2012.04324.x. Epub 2012 Nov 21. No abstract available.

7.

Of mice and men: terminal complement inhibition with anti-C5 monoclonal antibodies.

Woodle ES, Baldwin WM 3rd.

Am J Transplant. 2011 Nov;11(11):2277-8. doi: 10.1111/j.1600-6143.2011.03760.x. No abstract available.

8.

Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.

Libório AB, Mendoza TR, Esmeraldo RM, Oliveira ML, Paes FJ, Silva Junior GB, Daher EF.

Int Immunopharmacol. 2011 Nov;11(11):1832-6. doi: 10.1016/j.intimp.2011.07.012. Epub 2011 Aug 9.

PMID:
21835269
9.

Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab.

Alausa M, Almagro U, Siddiqi N, Zuiderweg R, Medipalli R, Hariharan S.

Clin Transplant. 2005 Feb;19(1):137-40.

PMID:
15659147
10.

[Research status and development of humanized anti-tumor antibody drugs].

He Y, Zhang J, Li ZK, Wang M.

Yao Xue Xue Bao. 2012 Oct;47(10):1269-74. Review. Chinese.

PMID:
23289137
11.

Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children.

Pollock-Barziv SM, Finkelstein Y, Manlhiot C, Dipchand AI, Hebert D, Ng VL, Solomon M, McCrindle BW, Grant D.

Pediatr Transplant. 2010 Dec;14(8):968-75. doi: 10.1111/j.1399-3046.2010.01409.x. Epub 2010 Oct 5.

PMID:
21040278
12.

In search of an optimal induction agent in kidney transplantation.

Sureshkumar KK, Chopra B.

Transplantation. 2014 Jul 15;98(1):e1-2. doi: 10.1097/TP.0000000000000208. No abstract available.

PMID:
24978038
13.

Perceived barriers to adherence among adolescent renal transplant candidates.

Zelikovsky N, Schast AP, Palmer J, Meyers KE.

Pediatr Transplant. 2008 May;12(3):300-8. doi: 10.1111/j.1399-3046.2007.00886.x. Epub 2008 Jan 7.

PMID:
18194352
14.

Development and validation of an immunosuppressant therapy adherence barrier instrument.

Chisholm MA, Lance CE, Williamson GM, Mulloy LL.

Nephrol Dial Transplant. 2005 Jan;20(1):181-8. Epub 2004 Nov 30.

15.

Depression and immunosuppressive medication adherence in kidney transplant patients.

Cukor D, Newville H, Jindal R.

Gen Hosp Psychiatry. 2008 Jul-Aug;30(4):386-7. doi: 10.1016/j.genhosppsych.2007.12.003. No abstract available.

PMID:
18585547
16.

Usefulness of 3-month protocol biopsy of kidney allograft to detect subclinical rejection under triple immunosuppression with basiliximab: a single center experience.

Masutani K, Kitada H, Tsuchimoto A, Yamada S, Noguchi H, Tsuruya K, Tanaka M, Iida M.

Clin Exp Nephrol. 2011 Apr;15(2):264-8. doi: 10.1007/s10157-010-0385-x. Epub 2010 Dec 21.

PMID:
21170758
17.

The author's reply.

Welberry Smith MP, Baker RJ.

Transplantation. 2014 Jul 15;98(1):e2-3. doi: 10.1097/TP.0000000000000206. No abstract available.

PMID:
24978039
18.

Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection.

Slavcev A, Lácha J, Honsová E, Sajdlová H, Lodererová A, Vitko S, Skibová J, Striz I.

Transpl Immunol. 2005 Jun;14(2):117-21. Epub 2005 Apr 25.

PMID:
15935302
19.

Rituximab as treatment for refractory kidney transplant rejection.

Becker YT, Becker BN, Pirsch JD, Sollinger HW.

Am J Transplant. 2004 Jun;4(6):996-1001.

20.

Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function.

Bumgardner GL, Ramos E, Lin A, Vincenti F; Daclizumab Triple Therapy and Double Therapy Groups.

Transplantation. 2001 Aug 27;72(4):642-7.

PMID:
11544424
Items per page

Supplemental Content

Write to the Help Desk